TransMedics Group, Inc. (TMDX)
NASDAQ: TMDX · Real-Time Price · USD
130.93
+7.11 (5.74%)
At close: Nov 21, 2025, 4:00 PM EST
131.09
+0.16 (0.12%)
After-hours: Nov 21, 2025, 7:43 PM EST
TransMedics Group Revenue
TransMedics Group had revenue of $143.82M in the quarter ending September 30, 2025, with 32.24% growth. This brings the company's revenue in the last twelve months to $566.35M, up 41.20% year-over-year. In the year 2024, TransMedics Group had annual revenue of $441.54M with 82.74% growth.
Revenue (ttm)
$566.35M
Revenue Growth
+41.20%
P/S Ratio
7.82
Revenue / Employee
$777,959
Employees
728
Market Cap
4.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 441.54M | 199.92M | 82.74% |
| Dec 31, 2023 | 241.62M | 148.16M | 158.53% |
| Dec 31, 2022 | 93.46M | 63.20M | 208.83% |
| Dec 31, 2021 | 30.26M | 4.62M | 18.03% |
| Dec 31, 2020 | 25.64M | 2.04M | 8.62% |
| Dec 28, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 29, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TMDX News
- 4 days ago - TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference - PRNewsWire
- 9 days ago - Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks - Benzinga
- 16 days ago - Polen U.S. Small Cap Growth Q3 2025 Portfolio Performance And Attribution - Seeking Alpha
- 22 days ago - TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 22 days ago - TransMedics: Growth Tailwinds Should Provide Upside In 2026 - Seeking Alpha
- 23 days ago - TransMedics: Q3 Results Disappointed, As Expected (Rating Upgrade) - Seeking Alpha
- 23 days ago - TransMedics Group, Inc. (TMDX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 24 days ago - TransMedics Reports Third Quarter 2025 Financial Results - PRNewsWire